LP
RCKTW icon

LMR Partners’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

LMR Partners’s Portfolio RCKTW Stock Details RCKTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60,771
Closed -$4.25K – 1531
2024
Q3 		$4.25K Buy
+60,771
New +$4.68K ﹤0.01% 1185

Other funds holding RCKTW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LMR Partners's RCKTW Position: Q1 2026 in Review

LMR Partners held its Rocket Pharmaceuticals Warrant (RCKTW) position steady in Q1 2026 at 75,731 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #1406.

LMR Partners first reported a position in RCKTW in Q2 2023 and has held it in 11 quarters since. The position peaked at $29.8K in Q4 2023. 10 funds tracked by Wall St. Rank hold RCKTW as of Q1 2026.

  • LMR Partners held 75,731 shares of Rocket Pharmaceuticals Warrant worth $1.56K as of Q1 2026.
  • LMR Partners left its Rocket Pharmaceuticals Warrant share count unchanged in Q1 2026.
  • Rocket Pharmaceuticals Warrant made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1406 holding.
  • LMR Partners first reported a position in Rocket Pharmaceuticals Warrant in Q2 2023 and has held it in 11 quarters since.
  • LMR Partners's Rocket Pharmaceuticals Warrant position peaked at $29.8K in Q4 2023.
  • 10 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.